PMID- 36923080
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230316
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 11
IP  - 4
DP  - 2023 Feb 28
TI  - A real-world retrospective study of incidence and associated factors of endocrine 
      adverse events related to PD-1/PD-L1 inhibitors.
PG  - 164
LID - 10.21037/atm-22-5459 [doi]
LID - 164
AB  - BACKGROUND: The adverse events (AEs) related to immune checkpoint inhibitors 
      (ICIs) have been mostly described in clinical trials, however, such trials are 
      restricted to selection criteria and the results cannot wholly represent the 
      real-world setting. We aimed to evaluate the real-world endocrine AEs associated 
      with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) 
      inhibitors in Chinese population. METHODS: This retrospective study included 
      cancer patients who were treated with PD-1/PD-L1 inhibitors between January 2018 
      and December 2020 at Xinqiao Hospital, the Third Military Medical University. The 
      information of 581 patients was reviewed, and data on clinical characteristics, 
      PD-1/PD-L1 use, occurrence of endocrine AEs, and response to PD-1 blockade 
      treatment were collated. The definition of endocrine AEs relied on diagnostic 
      tests. Fisher's exact test or Pearson's chi-squared test was used to analyze the 
      associations between endocrine variables and several categorical variables. 
      Multivariate analyses were performed using a logistic regression model. RESULTS: 
      Endocrine AEs were observed in 116 of the 581 patients (20.0%). The median time 
      to onset of endocrine AEs was approximately 12 weeks. Pembrolizumab was 
      associated with a significantly higher incidence of endocrine AEs compared to 
      other anti-PD-1 agents (38.5%; P=0.0002); PD-1/PD-L1 inhibitor treatment combined 
      with antiangiogenic therapy or with two other therapies (chemotherapy and 
      antiangiogenic therapy) was associated with a significantly increased occurrence 
      of endocrine AEs, compared to PD-1 blockade treatment alone (41.2%; P=0.015), 
      both based on multivariate analysis. Patients who developed endocrine AEs had 
      significantly higher overall response rates (ORRs; 33.3% vs. 23.1%, P=0.045) and 
      disease control rates (DCRs; 91.1% vs. 79.1%, P=0.008) compared to patients 
      without endocrine AEs. In multivariate analysis, endocrine AEs remained an 
      independent factor for both ORR (OR: 1.764, 95% CI: 1.052-2.957, P=0.031) and DCR 
      (OR: 2.896, 95% CI: 1.324-6.332, P=0.008) after adjusting for the confounding 
      factors. CONCLUSIONS: A real-world Chinese population receiving PD-1/PD-L1 
      treatment, pembrolizumab administrated and triple therapy treatment modalities 
      had a higher incidence of endocrine AEs. Patients who developed endocrine AEs 
      demonstrated a favorable response to PD-l blockade treatment.
CI  - 2023 Annals of Translational Medicine. All rights reserved.
FAU - Wang, Zhiyi
AU  - Wang Z
AD  - Institute of Cancer, Xinqiao Hospital, the Third Military Medical University, 
      Chongqing, China.
AD  - Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
FAU - Hu, Chunyan
AU  - Hu C
AD  - Institute of Cancer, Xinqiao Hospital, the Third Military Medical University, 
      Chongqing, China.
AD  - Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
FAU - Zhang, Anmei
AU  - Zhang A
AD  - Institute of Cancer, Xinqiao Hospital, the Third Military Medical University, 
      Chongqing, China.
AD  - Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
FAU - Wang, Xinxin
AU  - Wang X
AD  - Institute of Cancer, Xinqiao Hospital, the Third Military Medical University, 
      Chongqing, China.
AD  - Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
FAU - Zeng, Dong
AU  - Zeng D
AD  - Institute of Cancer, Xinqiao Hospital, the Third Military Medical University, 
      Chongqing, China.
AD  - Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
FAU - Long, Tao
AU  - Long T
AD  - Institute of Cancer, Xinqiao Hospital, the Third Military Medical University, 
      Chongqing, China.
AD  - Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
FAU - Zhu, Bo
AU  - Zhu B
AD  - Institute of Cancer, Xinqiao Hospital, the Third Military Medical University, 
      Chongqing, China.
AD  - Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
FAU - Wang, Zhongyu
AU  - Wang Z
AD  - Institute of Cancer, Xinqiao Hospital, the Third Military Medical University, 
      Chongqing, China.
AD  - Chongqing Key Laboratory of Immunotherapy, Chongqing, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC10009552
OTO - NOTNLM
OT  - Programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors
OT  - cancer
OT  - endocrine adverse events (AEs)
OT  - real-world evidence
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-5459/coif). Zhongyu Wang 
      reports funding support from the National Natural Science Foundation of China 
      (No. 82173097). The other authors have no conflicts of interest to declare.
EDAT- 2023/03/17 06:00
MHDA- 2023/03/17 06:01
PMCR- 2023/02/28
CRDT- 2023/03/16 02:16
PHST- 2022/10/09 00:00 [received]
PHST- 2023/02/10 00:00 [accepted]
PHST- 2023/03/16 02:16 [entrez]
PHST- 2023/03/17 06:00 [pubmed]
PHST- 2023/03/17 06:01 [medline]
PHST- 2023/02/28 00:00 [pmc-release]
AID - atm-11-04-164 [pii]
AID - 10.21037/atm-22-5459 [doi]
PST - ppublish
SO  - Ann Transl Med. 2023 Feb 28;11(4):164. doi: 10.21037/atm-22-5459.